Home » Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
Novo Nordisk has discontinued development of one of its four hemophilia drug candidates following data from a Phase IIIa trial that found anti-drug antibodies and further potential risks for hemophilia patients with inhibitors. The trial compared vatreptacog alfa with Novo’s FDA-approved NovoSeven [coagulation factor VIIa (recombinant)] to treat 567 bleeding episodes in 72 hemophiliacs.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May